Mizuho Maintains Buy on Arcus Biosciences, Lowers Price Target to $42-Report Released on 29 January 2024

Arcus Biosciences +2.74%

Arcus Biosciences




Mizuho analyst Mara Goldstein maintains Arcus Biosciences (NYSE: RCUS) with a Buy and lowers the price target from $51 to $42.
Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via